The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zhorzholadze N.V.

Research Institute of Eye Diseases

Sheremet N.L.

Krasnov Research Institute of Eye Diseases

Tanas A.S.

Research Centre for Medical Genetics

Strelnikov V.V.

Research Centre for Medical Genetics

New possibilities in the treatment of Stargardt disease

Authors:

Zhorzholadze N.V., Sheremet N.L., Tanas A.S., Strelnikov V.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(4): 333‑343

DOI: 10.17116/oftalma2020136042333

Read: 17326 times

Download PDF (RU)
Contact the author
Table of contents

NEW POSSIBILITIES IN THE TREATMENT OF STARGARDT DISEASE
NEW POSSIBILITIES IN THE TREATMENT OF STARGARDT DISEASE

To cite this article:

Zhorzholadze NV, Sheremet NL, Tanas AS, Strelnikov VV. New possibilities in the treatment of Stargardt disease. Russian Annals of Ophthalmology. 2020;136(4):333‑343. (In Russ.)
https://doi.org/10.17116/oftalma2020136042333

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Auto­logous adipose-derived stem cells for the treatment of complex cryptoglandular fistula (systematic review and meta-analysis). Plastic Surgery and Aesthetic Medi­cine. 2025;(2):117-127
Towa­rds highly precise treatment and reha­bilitation in practice of modern cardiologist, cardiac surgeon and cardiac reha­bilitation professional. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):343-350
The type 1 diabetes mellitus treatment. Russian Journal of Preventive Medi­cine. 2025;(8):131-137
DNA base editors are a promising tool to gene therapy of human viral infe­ctions. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(3):4-8
Influence of limb reva­scularization and therapeutic angiogenesis on concentration of angiogenic factors. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):539-546
Age-related pathomorphological changes in the brain of non-human primates. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4-2):143-149
Biomarkers of aging mechanisms. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(5-2):108-119
First expe­rience of the application of bere­magene gepe­rpavec gene­tically engi­neered drug for treatment of congenital dystrophic epidermolysis bullosa in the Russian Fede­ration. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):822-827
Characteristics of surgical and drug therapy for cardiac patients hospitalized in the Fede­ral Medi­cal Research Center. Russian Journal of Preventive Medi­cine. 2026;(1):20-27
Abstract:

Stargardt disease is a hereditary retinal dystrophy associated with mutations in the ABCA4 gene. Currently, no etiopathogenetic drugs nor treatment methods for Stargardt disease have completely passed clinical trials. The review summarizes experimental and clinical studies of drugs aimed at reducing the accumulation of vitamin A dimers, lipofuscin, complement inhibition and RPE regeneration by stem cell transplantation, as well as gene therapy studies with intravitreal vector injection of the ABCA4 functional gene.

Keywords:

Stargardt disease
retinal dystrophy
ABCA4 gene
retinal pigment epithelium
visual cycle
lipofuscin
pharmacological therapy
stem cells
gene therapy

Authors:

Zhorzholadze N.V.

Research Institute of Eye Diseases

Sheremet N.L.

Krasnov Research Institute of Eye Diseases

Tanas A.S.

Research Centre for Medical Genetics

Strelnikov V.V.

Research Centre for Medical Genetics

Received:

12.05.2020

Accepted:

17.06.2020

Close metadata

References:

  1. Gudzenko SV, Khlebnikova OV, Beklemitcheva NA, Polyakov AV. DNA-diagnostics of hereditary retinal dystrophies, caused by mutations in ABCA4 gene. Meditsinskaya genetika. 2006;5(9):37-40. (In Russ.).
  2. Sheffield VC, Stone EM. Genomics and the eye. The New England Journal of Medicine. 2011;364(20):1932-1942. https://doi.org/10.1056/nejmra1012354
  3. Schulz HL, Grassmann F, Kellner U, Spital G, Rüther K, Jägle H, Hufendiek K, Rating Ph, Huchzermeyer C, Baier MJ, Weber BHF, Stöhr H. Mutation Spectrum of the ABCA4 Gene in 335 Stargardt Disease Patients From a Multicenter German Cohort — Impact of Selected Deep Intronic Variants and Common SNPs. Investigative Ophthalmology and Visual Science. 2017; 58(1):394-403.  https://doi.org/10.1167/iovs.16-19936
  4. Ostorovskij MA, Fel’dman TB., Jakovleva MA, Lovjagina ER, Churkina LA, Kirpichnikov MP, Dolgih DA, Nekrasova OV, Korshun VA, Tahchidi HP, Borzenok SA, Shurigina MF, Ginter EK, Hlebnikova OV, Poljakov AV. Zritel’nyj cikl, belok ABCR4 i monogennoe zabolevanie setchatki glaza — bolezn’ SHtargardta (metody gennoj diagnostiki). Postgenomnye issledovanija i tehnologii: kollektivnaja monografija. M.: MAKS-Press; 2011. (In Russ.).
  5. Sokolov AV, Sokolov VS, Fel’dman TB, Ostrovskij MA. Interaction of pyridinium bis-trans-retinal with bilayer lipid membranes. Biologicheskie membrany. 2008;6:499-507. (In Russ.).
  6. Sokolov VS, Sokolenko EA, Sokolov AV, Dontsov AE, Chizmadzhev YA, Ostrovsky MA. Interaction of pyridinium bis-retinoid (A2E) with bilayer lipid membranes. Journal of Photochemistry and Photobiology, B: Biology. 2007;86(2):177-185.  https://doi.org/10.1016/j.jphotobiol.2006.09.006
  7. Costanzi S, Siegel J, Tikhonova IG, Jacobson KA. Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. Current Pharmaceutical Design. 2009;15(35):3994-4002. https://doi.org/10.2174/138161209789824795
  8. Ahn J, Wong JT, Molday RS. The effect of lipid environment and retinoids on the ATPase activity of ABCR, the photoreceptor ABC transporter responsible for Stargardt macular dystrophy. Journal of Biological Chemistry. 2000; 275(27):20399-20405. https://doi.org/10.1074/jbc.m000555200
  9. Maeda A, Maeda T, Sun W, Zhang H, Baehr W, Palczewski K. Redundant and unique roles of retinol dehydrogenases in the mouse retina. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(49):19565-19570. https://doi.org/10.1073/pnas.0707477104
  10. Sun H, Molday RS, Nathans J. Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease. Journal of Biological Chemistry. 1999;274(12):8269-8281. https://doi.org/10.1074/jbc.274.12.8269
  11. Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Advances in Experimental Medicine and Biology. 2010;703:105-125.  https://doi.org/10.1007/978-1-4419-5635-4_8
  12. Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis GH. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt’s disease from the phenotype in ABCR knockout mice. Cell. 1999;98(1):13-23.  https://doi.org/10.1016/s0092-8674(00)80602-9
  13. Loginova MJu, Rostovceva EV, Fel’dman TB, Ostrovskij MA. Light damaging action of all-trans-retinal and its derivatives on rhodopsin molecules in the photoreceptor membrane. Biohimija. 2008;73:162-172. (In Russ.). https://doi.org/10.1134/s000629790802003x
  14. Charbel IP, Barnard AR, Singh MS, Carter E, Jiang Z, Radu RA, Schraermeyer U, MacLaren RE. Fundus autofl uorescence in the Abca4 (–/–) mouse model of Stargardt disease — correlation with accumulation of A2E, retinal function, and histology. Investigative Ophthalmology and Visual Science. 2013;54(8):5602-5612. https://doi.org/10.1167/iovs.13-11688
  15. Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW, Lam BL. Stargardt macular dystrophy and evolving therapies. Expert Opinion on Biological Therapy. 2018;18(10):1049-1059. https://doi.org/10.1080/14712598.2018.1513486
  16. Louise JL, Ji L, Ron A. Adelman. Novel therapeutics for Stargardt disease. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2017;255(6): 1057-1062. https://doi.org/10.1007/s00417-017-3619-8
  17. Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE). Accessed June 23, 2020. https://clinicaltrials.gov/ct2/show/NCT02402660?term=NCT02402660&rank=1
  18. Scholl HP, Tsang SH, Kay CN, Connor TB, Gorin MB, Bernstein PS, Lam BL, Strecker Z, Zaremba JT, DeBartolomeo G, Washington I, Saad L. Stargardt disease ALK-001 phase 2 clinical trial: 12-month interim data. Investigative Ophthalmology and Visual Science. 2019;60(9):1336-1336.
  19. Charbel IP, Barnard AR, Herrmann P, Washington I, MacLaren RE. Rescue of the Stargardt phenotype in ABCA4 knockout mice through inhibition of Vitamin A dimerization. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(27):8415-8420. https://doi.org/10.1073/pnas.1506960112
  20. Saad L, Washington I. Can Vitamin A be improved to prevent blindness due to age-related macular degeneration, Stargardt disease and other retinal dystrophies? Advances in Experimental Medicine and Biology. 2016;854:355-361.  https://doi.org/10.1007/978-3-319-17121-0_47
  21. Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. 2013;33(3):498-507.  https://doi.org/10.1097/iae.0b013e318265801d
  22. Radu RA, Han Y, Bui TV, Nusinowitz S, Bok D, Lichter J, Widder K, Travis GH, Mata NL. Reductions in serum Vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Investigative Ophthalmology and Visual Science. 2005; 46(12):4393-4401. https://doi.org/10.1167/iovs.05-0820
  23. Dobri N, Qin Q, Kong J, Yamamoto K, Liu Z, Moiseyev G, Ma JX, Allikmets R, Sparrow JR, Petrukhin K. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. Investigative Ophthalmology and Visual Science. 2013;54(1):85-95.  https://doi.org/10.1167/iovs.12-10050
  24. Budzinskaja MV, Shelankova AV, Mihajlova MA, Pljuhova AA, Nurieva NM, Fomin AV. Analysis of changes in central macular thickness based on optical coherence tomography angiography findings in retinal vein occlusion. Vestnik oftal’mologii. 2016;132(5):15-22. (In Russ.). https://doi.org/10.17116/oftalma2016132515-22
  25. Kubota R, Boman NL, David R, Mallikaarjun S, Patil S, Birch D. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina. 2012;32(1):183-188.  https://doi.org/10.1097/iae.0b013e318217369e
  26. Rosenfeld PJ, Dugel PU, Holz FG, Heier JS, Pearlman JA, Novack RL, Csaky KG, Koester JM, Gregory JK, Kubota R. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial. Ophthalmology. 2018;125(10):1556-1567. https://doi.org/10.1016/j.ophtha.2018.03.059
  27. Maeda A, Golczak M, Chen Y, Okano K, Kohno H, Shiose S, Ishikawa K, Harte W, Palczewska G, Maeda T, Palczewski K. Primary amines protect against retinal degeneration in mouse models of retinopathies. Nature Chemical Biology. 2011;8(2):170-178.  https://doi.org/10.1038/nchembio.759
  28. Wu Y, Zhou J, Fishkin N, Rittmann BE. Sparrow JR. Enzymatic Degradation of A2E, a Retinal Pigment Epithelial Lipofuscin Bisretinoid. Journal of the American Chemical Society. 2011;133(4):849-857.  https://doi.org/10.1021/ja107195u
  29. Julien S, Schraermeyer U. Lipofuscin can be eliminated from the retinal pigment epithelium of monkeys. Neurobiology of Aging. 2012;33(10):2390-2397. https://doi.org/10.1016/j.neurobiolaging.2011.12.009
  30. Fang Y, Tschulakow A, Tikhonovich T, Taubitz T, Illing B, Schultheiss S, Schraermeyer U, Julien-Schraermeyer S. Preclinical results of a new pharmacological therapy approach for Stargardt Disease and dry age-related macular degeneration. Investigative Ophthalmology and Visual Science. 2017; 58(8):256. 
  31. Cao S, Wang JC, Gao J, Wong M, To E, White VA, Cui JZ, Matsubara JA. CFH Y402H polymorphism and the complement activation product C5a: effects on NF-kappaB activation and inflammasome gene regulation. British Journal of Ophthalmology. 2016;100(5):713-718.  https://doi.org/10.1136/bjophthalmol-2015-307213
  32. Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases. Accessed June 23, 2020. https://eyewire.news/articles/ophthotech-provides-update-on-zimura-complement-programs-for-treatment-of-eye-diseases/
  33. IVERIC Bio ‘s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. Accessed June 23, 2020. https://www.businesswire.com/news/home/20191028005259/en/IVERIC-bio%E2%80%99s-Zimura%C2%AE-Complement-C5-Inhibitor-Met
  34. Radu RA, Mata NL, Nusinowitz S, Liu X, Sieving PA, Travis GH. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt’s macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(8):4742-4747. https://doi.org/10.1073/pnas.0737855100
  35. Bazan NG. Omega-3 fatty acids, pro-in fl ammatory signaling and neuroprotection. Current Opinion in Clinical Nutrition and Metabolic Care. 2007; 10(2):136-141.  https://doi.org/10.1097/mco.0b013e32802b7030
  36. Trapani I, Toriello E, de Simone S, Colella P, Iodice C, Polishchuk EV, Sommella A, Colecchi L, Rossi S, Simonelli F, Giunti M, Bacci ML, Polishchuk RS, Auricchio A. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Human Molecular Genetics. 2015;24(23):6811-6825. https://doi.org/10.1093/hmg/ddv386
  37. Trapani I. Dual AAV Vectors for Stargardt Disease. Methods in Molecular Biology. 2018;1715:153-175.  https://doi.org/10.1007/978-1-4939-7522-8_11
  38. Dalkara D, Goureau O, Marazova K, Sahel JA. Let there be light: gene and cell therapy for blindness. Human Gene Therapy. 2016;27(2):134-147.  https://doi.org/10.1089/hum.2015.147
  39. Binley K, Widdowson P, Loader J, Kelleher M, Iqball S, Ferrige G, de Belin J, Carlucci M, Angell-Manning D, Hurst F, Ellis S, Miskin J, Fernandes A, Wong P, Allikmets R, Bergstrom C, Aaberg T, Yan J, Kong J, Gouras P, Prefontaine A, Vezina M, Bussieres M, Naylor S, Mitrophanous KA. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Investigative Ophthalmology and Visual Science. 2013;54:4061-4071. https://doi.org/10.1167/iovs.13-11871
  40. Kong J, Kim SR, Binley K, Pata I, Doi K, Mannik J, Zernant-Rajang J, Kan O, Iqball S, Naylor S, Sparrow JR, Gouras P, Allikmets R. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Therapy. 2008;15(19):1311-1320. https://doi.org/10.1038/gt.2008.78
  41. Oxford BioMedica Announces Ocular Clinical Programme Update. 19/11/2012. Accessed June 23, 2020. https://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-positive-dsmbreview-of-ongoing-retinostat-r-and-stargen-clinical-studies/
  42. Radu RA, Hu J, Yuan Q, Welch DL, Makshanoff J, Lloyd M, McMullen S, Travis GH, Bok D. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. Journal of Biological Chemistry. 2011;286(21):18593-18601. https://doi.org/10.1074/jbc.m110.191866
  43. Lenis TL, Sarfare S, Jiang Z, Lloyd MB, Bok D, Radu RA. Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(15):3987-3992. https://doi.org/10.1073/pnas.1620299114
  44. Delori F. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Investigative Ophthalmology and Visual Science. 1995;36:718-729. 
  45. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Experimental Eye Research. 2005;80(5):595-606.  https://doi.org/10.1016/j.exer.2005.01.007
  46. Sheremet NL, Zhorzholadze NV, Ronzina IA, Grushke IG, Kurbatov SA, Chukhrova AL, Loginova AN, Shcherbakova PO, Tanas AS, Polyakov AV, Strelnikov VV. Molecular genetics diagnosis of Stargardt disease. Vestnik oftalmologii. 2017;133(4):4-11. (In Russ.). https://doi.org/10.17116/oftalma201713344-11
  47. Thomson JA, Hokovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-1147. https://doi.org/10.1126/science.282.5391.1145
  48. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-1920. https://doi.org/10.1126/science.1151526
  49. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells. 2001;19(3):193-204.  https://doi.org/10.1634/stemcells.19-3-193
  50. Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, Itskovitz-Eldor J, Thomson JA. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Developmental Biology. 2000;227(2):271-278.  https://doi.org/10.1006/dbio.2000.9912
  51. Sheremet NL, Mikaelyan AA, Andreev AYu, Kiselev SL. Possibilities of treating retinal diseases in patients with damaged retinal pigment epithelium. Vestnik oftal’mologii. 2019;135(5-2):226-234. (In Russ.). https://doi.org/10.17116/oftalma2019135052226
  52. Qiu TG. Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells (MA09-hRPE) in Macular Degeneration. NPJ Regenerative Medicine. 2019;4:19.  https://doi.org/10.1038/s41536-019-0081-8
  53. Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium for the treatment of macular degeneration: an assessment at 4 years. Investigative Ophthalmology and Visual Science. 2016;57:1-9.  https://doi.org/10.1167/iovs.15-18681
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.